Akt1 and -2 inhibition diminishes terminal differentiation and enhances central memory CD8+ T-cell proliferation and survival

OncoImmunology

Volumn 4, Issue 5, 2015, Pages

  Eid, Rasha Abu ^a   Friedman, Kevin M ^a,b   Mkrtichyan, Mikayel ^a   Walens, Andrea ^a,c   King, William ^a   Janik, John ^a   Khleif, Samir N ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b BLUEBIRD BIO   (United States)

^c DUKE UNIVERSITY   (United States)

Author keywords

Akt; Central memory; Effector memory; Proliferation; T cells

Indexed keywords

GAMMA INTERFERON; GRANZYME B; HERMES ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 7 RECEPTOR; L SELECTIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TUMOR NECROSIS FACTOR;

ADOPTIVE TRANSFER; ANIMAL CELL; ARTICLE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CELL STIMULATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; FLOW CYTOMETRY; IC50; IMMUNOLOGICAL MEMORY; IMMUNOTHERAPY; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

EID: 84944463344     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1005448     Document Type: Article

References (26)

1. Kim EH, Suresh M. Role of PI3K/Akt signaling in memory CD8 T cell differentiation. Front Immunol 2013; 4:20; PMID:23378844
2. Klebanoff CA, Gattinoni L, Restifo NP. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev 2006; 211:214-24; PMID:16824130; http://dx.doi.org/10.1111/j.0105-2896.2006.00391.x
3. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401:708-12; PMID:10537110; http://dx.doi.org/ 10.1038/44385
4. Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, Palmer DC, Antony PA, Hwang ST, Rosenberg SA, et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A 2005; 102:9571-6; PMID:15980149; http://dx.doi.org/10.1073/ pnas.0503726102
5. WherryEJ,TeichgraberV,BeckerTC,MasopustD,Kaech SM, Antia R, , von Andrian UH, Ahmed R. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003; 4:225-34; PMID:12563257; http://dx.doi.org/10.1038/ni889
6. Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, Royal RE, Kammula U, Restifo NP, Hughes MS, et al. Tumor progression can occur despite the induction of very high levels of self/ tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 2005; 175:6169-76; PMID:16237114; http://dx.doi.org/10.4049/ jimmunol.175.9.6169
7. Roberts AD, Ely KH, Woodland DL. Differential contributions of central and effector memory T cells to recall responses. J Exp Med 2005; 202:123-33; PMID:15983064; http://dx.doi.org/10.1084/ jem.20050137
8. Wu F, Zhang W, Shao H, Bo H, Shen H, Li J, et al. Human effector T cells derived from central memory cells rather than CD8T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy. Cancer Lett 2013; 339(2):195-207.
9. Kim EH, Sullivan JA, Plisch EH, Tejera MM, Jatzek A, Choi KY, Suresh M. Signal integration by Akt regulates CD8 T cell effector and memory differentiation. J Immunol 2012; 188:4305-14; PMID:22467649; http://dx.doi.org/10.4049/jimmunol.1103568
10. Finlay D, Cantrell D. Phosphoinositide 3-kinase and the mammalian target of rapamycin pathways control T cell migration. Ann N Y Acad Sci 2010; 1183:149-57; PMID:20146713; http://dx.doi.org/10.1111/ j.1749-6632.2009.05134.x
11. Kane LP, Weiss A. The PI-3 kinase/Akt pathway and T cell activation: pleiotropic pathways downstream of PtdIns(3,4,5)P3. Immunol Rev 2003; 192:7-20; PMID:12670391; http://dx.doi.org/10.1034/j.1600-065X.2003.00008.x
12. Mao C, Tili EG, Dose M, Haks MC, Bear SE, Maroulakou I, Horie K, Gaitanaris GA, Fidanza V, Ludwig T, et al. Unequal contribution of Akt isoforms in the double-negative to double-positive thymocyte transition. J Immunol 2007; 178:5443-53; PMID:17442925; http://dx.doi.org/10.4049/ jimmunol.178.9.5443
13. Juntilla MM, Wofford JA, Birnbaum MJ, Rathmell JC, Koretzky GA. Akt1 and Akt2 are required for alphabeta thymocyte survival and differentiation. Proc Natl Acad Sci U S A 2007; 104:12105-10; PMID:17609365; http://dx.doi.org/10.1073/pnas.0705285104
14. Li Q, Rao R, Vazzana J, Goedegebuure P, Odunsi K, Gillanders W, Shrikant PA. Regulating mammalian target of rapamycin to tune vaccination-induced CD8 (+) T cell responses for tumor immunity. J Immunol 2012; 188:3080-7; PMID:22379028; http://dx.doi. org/10.4049/jimmunol.1103365
15. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, Larsen CP, Ahmed R. mTOR regulates memory CD8 T-cell differentiation. Nature 2009; 460:108-12; PMID:19543266; http://dx.doi. org/10.1038/nature08155
16. Mineharu Y, Kamran N, Lowenstein PR, Castro MG. Blockade of mTOR signaling via rapamycin combined with immunotherapy augments anti-glioma cytotoxic and memory t cells' functions. Mol Cancer Ther 2014; 13(12):3024-36; PMID:25256739
17. Kim HL. Antibody-based depletion of Foxp3+ T cells potentiates antitumor immune memory stimulated by mTOR inhibition. Oncoimmunology 2014; 3:e29081; PMID:25083329; http://dx.doi.org/10.4161/ onci.29081
18. Long SA, Buckner JH. Combination of rapamycin and IL-2 increases de novo induction of human CD4(+) CD25(+)FOXP3(+) T cells. J Autoimmun 2008; 30:293-302; PMID:18313267; http://dx.doi.org/ 10.1016/j.jaut.2007.12.012
19. Strauss L, Whiteside TL, Knights A, Bergmann C, Knuth A, Zippelius A. Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol 2007; 178:320-9; PMID:17182569; http://dx.doi.org/ 10.4049/jimmunol.178.1.320
20. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005; 105:4743-8; PMID:15746082; http://dx.doi.org/10.1182/blood-2004-10-3932
21. Basu S, Golovina T, Mikheeva T, June CH, Riley JL. Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. J Immunol 2008; 180:5794-8; PMID:18424697; http://dx.doi.org/10.4049/ jimmunol.180.9.5794
22. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65:7052-8; PMID:16103051; http://dx.doi.org/10.1158/0008-5472.CAN-05-0917
23. Abu-Eid R, Samara RN, Ozbun L, Abdalla MY, Berzofsky JA, Friedman KM, Mkrtichyan M, Khleif SN. Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway. Cancer Immunol Res 2014; 2:1080-9; PMID:25080445; http://dx.doi.org/ 10.1158/2326-6066.CIR-14-0095
24. Wen M, XuW, Ren L, Gao F, Cui N, Wen J, Li X, Lin L, Ma Z, Chen B, et al. Effector cells derived from naive T cells used in tumor immunotherapy of mice bearing B16 melanoma. Chin Med J (Engl) 2014; 127:1328-33; PMID:24709189
25. Hinrichs CS, Borman ZA, Gattinoni L, Yu Z, Burns WR, Huang J, Klebanoff CA, Johnson LA, Kerkar SP, Yang S, et al. Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 2011; 117:808-14; PMID:20971955; http://dx.doi.org/ 10.1182/blood-2010-05-286286
26. B6.Cg-Thy1a/Cy Tg(TcraTcrb)8Rest/J. The Jackson Laboratory; 2004. Available at: http://jaxmice.jax.org/ strain/005023.html